Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Single Dose Regimen Study of LMN-101 in Healthy Volunteers Challenged With Campylobacter Jejuni
Conditions
Interventions
LMN-101
Placebo
Locations
1
United States
Pharmaron
Baltimore, Maryland, United States
Start Date
February 21, 2022
Primary Completion Date
October 4, 2022
Completion Date
October 4, 2022
Last Updated
September 25, 2025
NCT03266068
NCT02884752
NCT01048112
Lead Sponsor
Lumen Bioscience, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions